-
Australian Journal of General Practice Mar 2023
Topics: Male; Humans; Prostate-Specific Antigen; Decision Making, Shared
PubMed: 36872085
DOI: 10.31128/AJGP-01-23-6692 -
Urologie (Heidelberg, Germany) Apr 2023
Topics: Male; Humans; Prostatic Neoplasms; Prostate-Specific Antigen; Hormones
PubMed: 37014381
DOI: 10.1007/s00120-023-02054-z -
ACS Sensors Oct 2018
Topics: Biomarkers; Biosensing Techniques; Immunoassay; Prostate-Specific Antigen
PubMed: 30360626
DOI: 10.1021/acssensors.8b01180 -
Urology Apr 2016
Topics: Anti-Bacterial Agents; Fluoroquinolones; Humans; Male; Prostate-Specific Antigen
PubMed: 27036677
DOI: 10.1016/j.urology.2015.11.047 -
Korean Journal of Radiology 2018The aim of this systematic review was to describe the characteristics of prostate-specific membrane antigen (PSMA)-targeting PET and their clinical applications in... (Review)
Review
The aim of this systematic review was to describe the characteristics of prostate-specific membrane antigen (PSMA)-targeting PET and their clinical applications in prostate cancer patients. There have been major strides in the design, synthesis of PSMA-targeting PET tracers over the past several years. PSMA-targeting PET tracers can be categorized, according to positron emitters and targeting strategies for the PSMA. The majority of PSMA PET studies has been focused on patients with biochemical recurrence, but additional values of PSMA PET have also been investigated for use in primary staging, treatment planning, response evaluation, and PSMA radioligand therapy. PSMA PET is expected to bring improvements in the management of patients, but the impact of improved diagnosis by PSMA on overall survival remains unanswered. Many challenges still await PSMA PET to expedite the use in the clinical practice. At this early stage, prospective multicenter trials are needed to validate the effectiveness and usefulness of PSMA PET.
Topics: Antibodies, Monoclonal; Choline; Contrast Media; Humans; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms
PubMed: 30174470
DOI: 10.3348/kjr.2018.19.5.819 -
Biochimica Et Biophysica Acta Aug 2014Prostate-specific antigen (PSA) is one of the most widely used tumor markers, and strongly correlates with the risk of harboring from prostate cancer (PCa). This risk is... (Review)
Review
Prostate-specific antigen (PSA) is one of the most widely used tumor markers, and strongly correlates with the risk of harboring from prostate cancer (PCa). This risk is visible already several years in advance but PSA has severe limitations for PCa detection with its low specificity and low negative predictive value. There is an urgent need for new biomarkers especially to detect clinically significant and aggressive PCa. From all PSA-based markers, the FDA-approved Prostate Health Index (phi) shows improved specificity over percent free and total PSA. Other serum kallikreins or sarcosine in serum or urine show more diverging data. In urine, the FDA-approved prostate cancer gene 3 (PCA3) has also proven its utility in the detection and management of early PCa. However, some aspects on its correlation with aggressiveness and the low sensitivity at very high values have to be re-examined. The detection of a fusion of the androgen regulated TMPRSS2 gene with the ERG oncogene (from the ETS family), which acts as transcription factor gene, in tissue of ~50% of all PCa patients was one milestone in PCa research. When combining the urinary assays for TMPRSS2:ERG and PCA3, an improved accuracy for PCa detection is visible. PCA3 and phi as the best available PCa biomarkers show an equal performance in direct comparisons.
Topics: Animals; Biomarkers, Tumor; Humans; Kallikreins; Male; Prostate-Specific Antigen; Prostatic Neoplasms
PubMed: 24727384
DOI: 10.1016/j.bbcan.2014.04.001 -
MMW Fortschritte Der Medizin May 2023
Topics: Male; Humans; Aged; Prostate-Specific Antigen
PubMed: 37202674
DOI: 10.1007/s15006-023-2655-z -
MMW Fortschritte Der Medizin Aug 2023
Topics: Male; Humans; Early Detection of Cancer; Prostatic Neoplasms; Prostate-Specific Antigen
PubMed: 37537437
DOI: 10.1007/s15006-023-2842-y -
Current Opinion in Urology Jan 2020In this review, we present an update on the safety and efficacy of prostate-specific membrane antigen (PSMA) radioligand therapy (PRLT) of metastatic... (Review)
Review
PURPOSE OF REVIEW
In this review, we present an update on the safety and efficacy of prostate-specific membrane antigen (PSMA) radioligand therapy (PRLT) of metastatic castration-resistant prostate cancer (mCRPC).
RECENT FINDINGS
Treatment of mCRPC with approved treatment agents leads to a survival advantage. The disease often progresses despite these treatments. PRLT with Lutetium-177 and Actinium-225 labeled with PSMA (LuPSMA and AcPSMA) have recently been shown to be effective and well tolerated for mCRPC treatment. LuPSMA is currently applied in patients who have exhausted approved treatment options or in whom these approved treatments are contraindicated. In this category of heavily pretreated patients, prostate-specific antigen (PSA) response (≥50% decline) is achieved in about 46% of patients. Side-effects are tolerable with rare reports of grade III-IV treatment-induced toxicity. AcPSMA is currently applied on a smaller scale in patients who relapsed after LuPSMA or in whom LuPSMA is contraindicated. PSA response occurs in up to 88% of patients treated with AcPSMA.
SUMMARY
PRLT with LuPSMA and AcPSMA is a well-tolerated and effective treatment modality for mCRPC. Prospective randomized control trials are necessary to facilitate its application as an approved therapy option.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Treatment Outcome
PubMed: 31644433
DOI: 10.1097/MOU.0000000000000685 -
The Journal of Urology Feb 2020
Topics: Humans; Lasers, Solid-State; Male; Prostate; Prostate-Specific Antigen
PubMed: 31661373
DOI: 10.1097/01.JU.0000612532.27564.25